Mauna Kea Technologies announced that Cellvizio is being installed at the University College Cork - APC Microbiome Ireland, a Science Foundation Ireland research center for Inflammatory Bowel Disease (IBD) applications under the leadership of Prof. Marietta Iacucci. This is also the first installation of Cellvizio in Ireland for clinical purposes.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.39 EUR | +2.77% | 0.00% | -17.20% |
Apr. 25 | Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024 | CI |
Apr. 03 | Mauna Kea: first Italian center for Cellvizio | CF |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.20% | 25.62M | |
-12.91% | 19.08B | |
-46.21% | 2.65B | |
+18.15% | 1.87B | |
-3.12% | 1.61B | |
+23.78% | 1.21B | |
-10.69% | 1.02B | |
-20.89% | 905M | |
-7.14% | 716M | |
-18.10% | 682M |
- Stock Market
- Equities
- ALMKT Stock
- News Mauna Kea Technologies
- Mauna Kea Technologies Announces the Installation of Cellvizio at University College Cork - APC Microbiome Ireland for Inflammatory Bowel Disease Applications